

# Chapter 63

## Collagens, Elastic Fibers, and Other Extracellular Matrix Proteins of the Dermis

Thomas Krieg, Monique Aumailley,  
Manuel Koch, Mon-Li Chu, & Jouni Uitto

### REFERENCES

1. Hohenester E, Engel J: Domain structure and organisation in extracellular matrix proteins. *Matrix Biol* **21**:115, 2002
2. Hynes RO: The extracellular matrix: Not just pretty fibrils. *Science* **326**:1216, 2009
3. Tsang KY et al: The developmental roles of the extracellular matrix: Beyond structure to regulation. *Cell Tissue Res* **339**:93, 2010
4. Rozario T, DeSimone DW: The extracellular matrix in development and morphogenesis: A dynamic view. *Dev Biol* **341**:126, 2010
5. Ingber D: Tensegrity II. How structural networks influence cellular information processing networks. *J Cell Sci* **116**:1397, 2003
6. Brown AE, Discher DE: Conformational changes and signaling in cell and matrix physics. *Curr Biol* **19**:R781, 2009
7. Buxboim A et al: Matrix elasticity, cytoskeletal forces and physics of the nucleus: How deeply do cells 'feel' outside and in? *J Cell Sci* **123**:297, 2010
8. Eckes B, Krieg T: Regulation of connective tissue homeostasis in the skin by mechanical forces. *Clin Exp Rheumatol* **22**:S73, 2004
9. Myllyharju J, Kivirikko KI: Collagens, modifying enzymes and their mutations in humans, flies and worms. *Trends Genet* **20**:33, 2004
10. Heino J: The collagen family members as cell adhesion proteins. *Bioessays* **29**:1001, 2007
11. Gordon MK, Hahn RA: Collagens. *Cell Tissue Res* **339**:247, 2010
12. Brodsky B, Persikov AV: Molecular structure of the collagen triple helix. *Adv Protein Chem* **70**:301, 2005
13. Myllyharju J, Kivirikko KI: Collagens and collagen-related diseases. *Ann Med* **33**:7, 2001
14. Pulkkinen L et al: Progress in heritable skin diseases: Molecular bases and clinical implications. *J Am Acad Dermatol* **47**:91, 2002
15. Kuivaniemi H et al: Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. *Hum Mutat* **9**:300, 1997
16. Mikkola ML: Molecular aspects of hypohidrotic ectodermal dysplasia. *Am J Med Genet A* **149A**:2031, 2009
17. Bruckner P: Suprastructures of extracellular matrices: Paradigms of functions controlled by aggregates rather than molecules. *Cell Tissue Res* **339**:7, 2010
18. Epstein EH Jr:  $[a1(3)]_3$  human skin collagen. Release by pepsin digestion and preponderance in fetal life. *J Biol Chem* **249**:3225, 1974
19. Mitchell AL et al: Molecular mechanisms of classical Ehlers-Danlos syndrome (EDS). *Hum Mutat* **30**:995, 2009
20. Callewaert B et al: Ehlers-Danlos syndromes and Marfan syndrome. *Best Pract Res Clin Rheumatol* **22**:165, 2008
21. Khoshnoodi J et al: Mammalian collagen IV. *Microsc Res Tech* **71**:357, 2008
22. Gould DB et al: Role of COL4A1 in small-vessel disease and hemorrhagic stroke. *N Engl J Med* **354**:1489, 2006
23. Hudson BG et al: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. *N Engl J Med* **348**:2543, 2003
24. Ghohestani RF et al: The  $\alpha 5$  chain of type IV collagen is the target of IgG autoantibodies in a novel autoimmune disease with subepidermal blisters and renal insufficiency. *J Biol Chem* **275**:16002, 2000
25. Engel J et al: Structure and macromolecular organization of type VI collagen. *Ann NY Acad Sci* **460**:25, 1985
26. Timpl R, Chu M-L: Microfibrillar collagen type VI. In: *Extracellular Matrix Assembly and Structure*, edited by PD Yurchenco, DE Birk, RP Mecham. San Diego, Academic Press, 1994, p. 207

27. Lampe AK, Bushby KM: Collagen VI related muscle disorders. *J Med Genet* **42**:673, 2005
28. Burgeson RE: Type VII collagen, anchoring fibrils, and epidermolysis bullosa. *J Invest Dermatol* **101**:252, 1993
29. Chung HJ, Uitto J: Type VII collagen: The anchoring fibril protein at fault in dystrophic epidermolysis bullosa. *Dermatol Clin* **28**:93, 2010
30. Bruckner-Tuderman L: Dystrophic epidermolysis bullosa: Pathogenesis and clinical features. *Dermatol Clin* **28**:107, 2010
31. Varki R et al: Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. *J Med Genet* **44**:181, 2007
32. Shaw LM, Olsen BR: FACIT collagens: Diverse molecular bridges in extracellular matrices. *Trends Biochem Sci* **16**:191, 1991
33. Marneros AG, Olsen BR: Physiological role of collagen XVIII and endostatin. *FASEB J* **19**:716, 2005
34. Ortega N, Werb Z: New functional roles for non-collagenous domains of basement membrane collagens. *J Cell Sci* **115**:4201, 2002
35. Franzke CW et al: Collagenous transmembrane proteins: Recent insights into biology and pathology. *J Biol Chem* **280**:4005, 2005
36. Nonaka S et al: The extracellular domain of BPAG2 has a loop structure in the carboxy terminal flexible tail in vivo. *J Invest Dermatol* **115**:889, 2000
37. Gatalica B et al: Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa. *Am J Hum Genet* **60**:352, 1997
38. Tasanen K et al: Keratinocytes from patients lacking collagen XVII display a migratory phenotype. *Am J Pathol* **164**:2027, 2004
39. Stanley JR et al: Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. *J Clin Invest* **70**:281, 1982
40. Jonkman MF et al: 180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. *J Clin Invest* **95**:1345, 1995
41. Chu M-L, Prockop DJ: Collagen: Gene structure. In: *Connective Tissue and Its Heritable Disorders: Molecular, Genetic and Medical Aspects*, 2nd edition, edited by PM Royce, B Steinmann. New York, Wiley-Liss, 2002, p. 223
42. Myllyharju M: Prolyl-4-hydroxylases, the key enzymes of collagen biosynthesis. *Matrix Biol* **22**:15, 2003
43. Krane SM: The importance of proline residues in the structure, stability and susceptibility to proteolytic degradation of collagens. *Amino Acids* **35**:703, 2008
44. Gorres KL, Raines RT: Prolyl 4-hydroxylase. *Crit Rev Biochem Mol Biol* **45**:106, 2010
45. Myllylä R et al: Expanding the lysyl hydroxylase toolbox: New insights into the localization and activities of lysyl hydroxylase 3 (LH3). *J Cell Physiol* **212**:323, 2007
46. Davidson JM et al: Ascorbate differentially regulates elastin and collagen biosynthesis in vascular smooth muscle cells and skin fibroblasts by pretranslational mechanisms. *J Biol Chem* **272**:345, 1997
47. Uitto J, Prockop DJ: Synthesis and secretion of under-hydroxylated procollagen at various temperatures by cells subject to temporary anoxia. *Biochem Biophys Res Commun* **60**:414, 1974
48. Myllyharju J: HIF prolyl 4-hydroxylases and their potential as drug targets. *Curr Pharm Des* **15**:3878, 2009
49. Berra E et al: The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. *EMBO Rep* **7**:41, 2006
50. Robins SP: Biochemistry and functional significance of collagen cross-linking. *Biochem Soc Trans* **35**:849, 2007
51. Salo AM et al: A connective tissue disorder caused by mutations of the lysyl hydroxylase 3 gene. *Am J Hum Genet* **83**:495, 2008
52. Prockop DJ et al: Procollagen N-proteinase and procollagen C-proteinase. Two unusual metalloproteinases that are essential for procollagen processing probably have important roles in development and cell signaling. *Matrix Biol* **16**:399, 1998
53. Apte SS: A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: Functions and mechanisms. *J Biol Chem* **284**:31493, 2009
54. Kessler E et al: Bone morphogenetic protein-1: The type I procollagen C-proteinase. *Science* **271**:360, 1996
55. Takahara K et al: Type I procollagen COOH-terminal proteinase enhancer protein: identification, primary structure, and chromosomal localization of the cognate human gene (PCOLCE). *J Biol Chem* **269**:26280, 1994
56. Colige A et al: Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. *Am J Hum Genet* **65**:308, 1999

57. Byers PH et al: Ehlers-Danlos syndrome type VIIA and VIIB result from splice-junction mutations or genomic deletions that involve exon 6 in the COL1A1 and COL1A2 genes of type I collagen. *Am J Med Genet* **72**:94, 1997
58. Rucker RB, Murray J: Cross-linking amino acids in collagen and elastin. *Am J Clin Nutr* **31**:1221, 1978
59. Gasch AT et al: Menkes disease. *Ophthalmology* **106**:442, 1999
60. Uitto J, Kouba D: Cytokine modulation of extracellular matrix gene expression: Relevance to fibrotic skin diseases. *J Dermatol Sci* **24**:S60, 2000
61. Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. *N Engl J Med* **360**:1989, 2009
62. Karsenty G, Park RW: Regulation of type I collagen genes expression. *Int Rev Immunol* **12**:177, 1995
63. Ramirez F et al: Transcriptional regulation of the human  $\alpha 2(I)$  collagen gene (COL1A2), an informative model system to study fibrotic diseases. *Matrix Biol* **25**:365, 2006
64. Griffiths CE et al: Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). *N Engl J Med* **329**:530, 1993
65. Verrecchia F, Mauviel A: TGF- $\beta$  and TNF- $\alpha$ : Antagonistic cytokines controlling type I collagen gene expression. *Cell Signal* **16**:873, 2004
66. Ferreira AM et al: Diminished induction of skin fibrosis in mice with MCP-1 deficiency. *J Invest Dermatol* **126**:1900, 2006
67. Nagase H, Woessner JF, Jr.: Matrix metalloproteinases. *J Biol Chem* **274**:21491, 1999
68. Page-McCaw A et al: Matrix metalloproteinases and the regulation of tissue remodelling. *Nat Rev Mol Cell Biol* **8**:221, 2007
69. Kessenbrock K et al: Matrix metalloproteinases: Regulators of the tumor microenvironment. *Cell* **141**:52, 2010
70. Bode W, Maskos K: Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. *Biol Chem* **384**:863, 2003
71. Brew K, Nagase H: The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. *Biochim Biophys Acta* **1803**:55, 2010
72. Gross J, Lapière CM: Collagenolytic activity in amphibian tissues: A tissue culture assay. *Proc Natl Acad Sci USA* **48**:1014, 1962
73. Bauer EA et al: Collagenase production by human skin fibroblasts. *Biochem Biophys Res Commun* **64**:232, 1975
74. Krane et al: Different collagenase gene products have different roles in degradation of type I collagen. *J Biol Chem* **271**:28509, 1996
75. Saffarian S et al: Interstitial collagenase is a Brownian ratchet driven by proteolysis of collagen. *Science* **306**:108, 2004
76. Midwood KS, Schwarzbauer JE: Elastic fibers: Building bridges between cells and their matrix. *Curr Biol* **12**:R279, 2002
77. Kielty CM: Elastic fibres in health and disease. *Expert Rev Mol Med* **8**:1, 2006
78. Uitto J et al: Elastic fibers in human skin: Quantitation of elastic fibers by computerized digital image analyses and determination of elastin by radioimmunoassay of desmosine. *Lab Invest* **49**:499, 1983
79. Akagawa M, Suyama K: Mechanism of formation of elastin crosslinks. *Connect Tissue Res* **41**:131, 2000
80. Sandberg LB, Davidson JM: Elastin and its gene. *Pept Prot Rev* **3**:169, 1984
81. Fazio MJ et al: Cloning of full-length elastin cDNAs from a human skin fibroblast recombinant cDNA library: Further elucidation of alternative splicing utilizing exon-specific oligonucleotides. *J Invest Dermatol* **91**:458, 1988
82. Bashir M et al: Characterization of the complete human elastin gene. *J Biol Chem* **264**:8887, 1989
83. Fazio MJ et al: Isolation and characterization of human elastin cDNAs, and age-associated variation in elastin gene expression in cultured skin fibroblasts. *Lab Invest* **58**:270, 1988
84. Indik Z et al: Alternative splicing of human elastin mRNA demonstrated by sequence analysis of cloned genomic and complementary DNA. *Proc Natl Acad Sci U S A* **84**:5680, 1987
85. Kahari VM et al: Deletion analyses of 5' flanking region of the human elastin gene. Delineation of functional promoter and regulatory cis-elements. *J Biol Chem* **265**:9485, 1990
86. Hsu-Wong S et al: Tissue-specific and developmentally regulated expression of human elastin promoter activity in transgenic mice. *J Biol Chem* **269**:18072, 1994
87. Hormuzdi SG et al: A gene-targeting approach identifies a function for the first intron in expression of the  $\alpha 1(I)$  collagen gene. *Mol Cell Biol* **18**:3368, 1998
88. Kahari VM et al: Tumor necrosis factor- $\alpha$  down-regulates human elastin gene expression. Evidence for the role of AP-1 in the suppression of promoter activity. *J Biol Chem* **267**:26134, 1992

89. Kahari VM et al: Transforming growth factor- $\beta$  up-regulates elastin gene expression in human skin fibroblasts. Evidence for post-transcriptional modulation. *Lab Invest* **66**:580, 1992
90. Pierce RA et al: 1,25-Dihydroxyvitamin D<sub>3</sub> represses tropoelastin expression by a posttranscriptional mechanism. *J Biol Chem* **267**:11593, 1992
91. Wolfe BL et al: Insulin-like growth factor-I regulates transcription of the elastin gene. *J Biol Chem* **268**:12418, 1993
92. Giro MG et al: Quantitation of elastin production in cultured vascular smooth muscle cells by a sensitive and specific enzyme-linked immunoassay. *Collagen Rel Res* **4**:21, 1984
93. Rosenbloom J, Cywinski A: Inhibition of proline hydroxylation does not inhibit secretion of tropoelastin by chick aorta cells. *FEBS Lett* **65**:246, 1976
94. Molnar J et al: Structural and functional diversity of lysyl oxidase and the LOX-like proteins. *Biochim Biophys Acta* **1647**:220, 2003
95. Lucero HA, Kagan HM: Lysyl oxidase: An oxidative enzyme and effector of cell function. *Cell Mol Life Sci* **63**:2304, 2006
96. Rucker RB: Isolation of soluble elastin from copper-deficient chick aorta. *Methods Enzymol* **82A**:559, 1982
97. Kuivaniemi H et al: Abnormal copper metabolism and deficient lysyl oxidase activity in a heritable connective tissue disorder. *J Clin Invest* **69**:710, 1983
98. Antonicelli F et al: Elastin-elastases and inflammation. *Curr Top Dev Biol* **79**:99, 2007
99. Uitto J: Biochemistry of the elastic fibers in normal connective tissues and its alterations in diseases. *J Invest Dermatol* **72**:1, 1979
100. Werb Z et al: Elastase and elastin degradation. *J Invest Dermatol* **79**:154s, 1982
101. Senior RM et al: Comparison of the elastolytic effects of human leukocyte elastase and porcine pancreatic elastase. *Adv Exp Med Biol* **79**:249, 1977
102. Shapiro SD et al: Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. *J Biol Chem* **268**:23824, 1993
103. Hubmacher D et al: Fibrillins: From biogenesis of microfibrils to signaling functions. *Curr Top Dev Biol* **75**:93, 2006
104. Ramirez F, Sakai LY: Biogenesis and function of fibrillin assemblies. *Cell Tissue Res* **339**:71, 2010
105. Ramirez F et al: Extracellular microfibrils in development and disease. *Cell Mol Life Sci* **64**:2437, 2007
106. Jovanović J et al: Fibrillin-integrin interactions in health and disease. *Biochem Soc Trans* **36**:257, 2008
107. Ramirez F, Rifkin DB. Extracellular microfibrils: Contextual platforms for TGF $\beta$  and BMP signaling. *Curr Opin Cell Biol* **21**:616, 2009
108. Rifkin DB: Latent transforming growth factor- $\beta$  (TGF- $\beta$ ) binding proteins: Orchestrators of TGF- $\beta$  availability. *J Biol Chem* **280**:7409, 2005
109. Hyytiäinen M et al: Latent TGF- $\beta$  binding proteins: Extracellular matrix association and roles in TGF- $\beta$  activation. *Crit Rev Clin Lab Sci* **41**:233, 2004
110. Karonen T et al: Transforming growth factor  $\beta$ 1 and its latent form binding protein-1 associate with elastic fibres in human dermis: Accumulation in actinic damage and absence in aneto-derma. *Br J Dermatol* **137**:51, 1997
111. Timpl R et al: Fibulins: A versatile family of extracellular matrix proteins. *Nat Rev Mol Cell Biol* **4**:479, 2003.
112. de Vega S et al: Fibulins: Multiple roles in matrix structures and tissue functions. *Cell Mol Life Sci* **66**:1890, 2009
113. McLaughlin PJ et al: Targeted disruption of fibulin-4 abolishes elastogenesis and causes perinatal lethality in mice. *Mol Cell Biol* **26**:1700, 2006
114. Nakamura T et al: Fibulin-5/DANCE is essential for elastogenesis in vivo. *Nature* **415**:171, 2002
115. Yanagisawa H et al: Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. *Nature* **415**:168, 2002
116. Loeys B et al: Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. *Hum Mol Genet* **11**:2113, 2002
117. Markova D et al: Genetic heterogeneity of cutis laxa: A heterozygous tandem duplication within the fibulin-5 (FBLN5) gene. *Am J Hum Genet* **72**:998, 2003
118. Huchtagowder V et al: Fibulin-4: A novel gene for an autosomal recessive cutis laxa syndrome. *Am J Hum Genet* **78**:1075, 2006
119. Colombatti A et al: The EMILIN protein family. *Matrix Biol* **19**:289, 2000
120. Wagenseil J, Mecham RP: New insights into elastic fiber assembly. *Birth Defects Res C Embryo Today* **81**:229, 2007
121. Esko JD, Lindahl U: Molecular diversity of heparan sulfate. *J Clin Invest* **108**:169, 2001

122. Esko JD et al: Proteoglycans and sulfated glycosaminoglycans. In: *Essentials of Glycobiology*, 2nd edition, edited by A Varki, RD Cummings, JD Esko, HH Freeze, P Stanley, CR Bertozzi, GW Hart, ME Etzler. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 2009. Chapter 16
123. Kolset SO, Tveit H: Serglycin—Structure and biology. *Cell Mol Life Sci* **65**:1073, 2008
124. Bernfield et al: Functions of cell surface heparan sulphate proteoglycans. *Annu Rev Biochem* **68**:729, 1999
125. Fransson LA et al: Biosynthesis of decorin and glypican. *Matrix Biol* **19**:367, 2000
126. David G: Integral membrane heparan sulfate proteoglycans. *FASEB J* **7**:1023, 1993
127. Lundqvist K, Schmidtchen A: Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers. *Br J Dermatol* **144**:254, 2001
128. Multhaupt HA et al: Syndecan signaling: When, where and why? *J Physiol Pharmacol* **60**:31, 2009
129. Lambaerts K et al: The signaling mechanisms of syndecan heparan sulfate proteoglycans. *Curr Opin Cell Biol* **21**:662, 2009
130. Rapraeger AC: Molecular interactions of syndecans during development. *Semin Cell Dev Biol* **12**:107, 2001
131. Sanderson RD et al: Syndecan-1, a cell-surface proteoglycan, changes in size and abundance when keratinocytes stratify. *J Invest Dermatol* **99**:390, 1992
132. Gallo R et al: Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. *J Invest Dermatol* **107**:676, 1996
133. Inki P, Jalkanen M: The role of syndecan-1 in malignancies. *Ann Med* **28**:63, 1996
134. Hirabayashi K et al: Altered proliferative and metastatic potential associated with increased expression of syndecan-1. *Tumour Biol* **19**:454, 1998
135. Gallagher JT: The extended family of proteoglycans: Social residents of the pericellular zone. *Curr Opin Cell Biol* **1**:1201, 1989
136. Kinsella MG et al: The regulated synthesis of versican, decorin, and biglycan: Extracellular matrix proteoglycans that influence cellular phenotype. *Crit Rev Eukaryot Gene Expr* **14**:203, 2004
137. Tiedemann K et al: Cytokine regulation of proteoglycan production in fibroblasts: Separate and synergistic effects. *Matrix Biol* **15**:469, 1997
138. Keene DR et al: Decorin binds near the C terminus of type I collagen. *J Biol Chem* **275**:21801, 2000
139. Elefteriou F et al: Binding of tenascin-X to decorin. *FEBS Lett* **495**:44, 2001
140. Danielson KG et al: Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. *J Cell Biol* **136**:729, 1997
141. Iozzo RV: Basement membrane proteoglycans: From cellar to ceiling. *Nat Rev Mol Cell Biol* **6**:646, 2005
142. Ornitz DM, Itoh N: Fibroblast growth factors. *Genome Biol* **2**:S3005, 2001
143. Loo BM, Salmivirta M: Heparin/Heparan sulfate domains in binding and signaling of fibroblast growth factor 8b. *J Biol Chem* **277**:32616, 2002
144. Sergeant N et al: Stimulation of DNA synthesis and cell proliferation of human mammary myoepithelial-like cells by hepatocyte growth factor/scatter factor depends on heparan sulfate proteoglycans and sustained phosphorylation of mitogen-activated protein kinases p42/44. *J Biol Chem* **275**:17094, 2000
145. Tessler S et al: Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. *J Biol Chem* **269**:12456, 1994
146. Pellegrini L et al: Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. *Nature* **407**:1029, 2000
147. Jiang D et al: Hyaluronan in tissue injury and repair. *Annu Rev Cell Dev Biol* **23**:435, 2007
148. Leitinger B, Hohenester E: Mammalian collagen receptors. *Matrix Biol* **26**:146, 2007
149. Dogic D, Eckes B, Aumailley M: Extracellular matrix, integrins and focal adhesions. *Curr Top Pathol* **93**:75, 1999
150. Watt F: Role of integrins in regulating epidermal adhesion, growth and differentiation. *EMBO J* **21**:3919, 2002
151. Larsen M et al: The matrix reorganized: Extracellular matrix remodeling and integrin signaling. *Curr Opin Cell Biol* **18**:463, 2006
152. Barczyk M et al: Integrins. *Cell Tissue Res* **339**:269, 2010
153. Eckes B et al: Mechanical tension and integrin  $\alpha 2\beta 1$  regulate fibroblast functions. *J Invest Dermatol Symp Proc* **11**:66, 2006.
154. Zollner TM et al: Targeting leukocyte trafficking to inflamed skin: Still an attractive therapeutic approach? *Exp Dermatol* **16**:1, 2007

155. Margadant C, Sonnenberg A: Integrin–TGF- $\beta$  crosstalk in fibrosis, cancer and wound healing. *EMBO Rep* 11:97, 2010
156. Ramirez F, Dietz HC: Extracellular microfibrils in vertebrate development and disease processes. *J Biol Chem* 284:14677, 2009
157. Brooke BS et al: Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med* 358:2787, 2008
158. Brown EL et al: Resistance to Lyme disease in decorin-deficient mice. *J Clin Invest* 107:845, 2001
159. Carrino DA et al: Age-related changes in the proteoglycans of human skin. *Arch Biochem Biophys* 373:91, 2000
160. Ghersetich I et al: Hyaluronic acid in cutaneous intrinsic aging. *Int J Dermatol* 33:119, 1994
161. Lundin A et al: Topical retinoic acid treatment of photoaged skin: Its effects on hyaluronan distribution in epidermis and on hyaluronan and retinoic acid in suction blister fluid. *Acta Derm Venereol* 72:423, 1992
162. Alaish SM et al: Hyaluronic acid metabolism in keloid fibroblasts. *J Pediatr Surg* 30:949, 1995
163. Lamandé SR et al: Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro $\alpha$ 1(I) chain carboxyl-terminal propeptide which impair subunit assembly. *J Biol Chem* 270:8642, 1995
164. Pace JM et al: A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the pro $\alpha$ 1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseases. *J Med Genet* 39:23, 2002
165. Firtina Z et al: Abnormal expression of collagen IV in lens activates unfolded protein response resulting in cataract. *J Biol Chem* 284:35872, 2009
166. Lin JH et al: Endoplasmic reticulum stress in disease pathogenesis. *Annu Rev Pathol* 3:399, 2008
167. Bateman JF et al: Genetic diseases of connective tissues: Cellular and extracellular effects of ECM mutations. *Nat Rev Genet* 10:173, 2009
168. Boot-Handford RP, Briggs MD: The unfolded protein response and its relevance to connective tissue diseases. *Cell Tissue Res* 339:197, 2010